Crispr Therapeutics (NASDAQ:CRSP) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, November 30th, BidAskClub reports.
Several other analysts have also recently issued reports on the company. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Roth Capital raised their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Finally, TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $69.54.
Shares of Crispr Therapeutics stock opened at $72.37 on Friday. The firm’s 50-day moving average is $54.81 and its two-hundred day moving average is $47.38. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Equities analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at approximately $465,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Nikko Asset Management Americas Inc. lifted its stake in shares of Crispr Therapeutics by 324.3% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after buying an additional 1,430,364 shares during the period. ARK Investment Management LLC increased its position in shares of Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the period. Orbimed Advisors LLC purchased a new position in Crispr Therapeutics in the 3rd quarter worth $21,167,000. Price T Rowe Associates Inc. MD raised its stake in Crispr Therapeutics by 19.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares during the last quarter. 49.81% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How to Invest in Stocks with Increasing Dividends
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.